Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

ClinicalTrials.gov ID: NCT01111539

Public ClinicalTrials.gov record NCT01111539. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 12:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder

Study identification

NCT ID: NCT01111539
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Enrollment: 211 participants

Conditions and interventions

Conditions

Major Depressive Disorder (MDD)

Interventions

Aripiprazole Drug
Blinded capsule Drug
Escitalopram Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 12, 2010
Primary completion: Sep 19, 2011
Completion: Sep 19, 2011
Last update posted: Oct 19, 2021

2010 – 2011

United States locations

U.S. sites: 24
U.S. states: 14
U.S. cities: 24

Facility	City	State	ZIP	Site status
Not listed	Cerritos	California	90703	—
Not listed	Costa Mesa	California	92626	—
Not listed	Irvine	California	92618	—
Not listed	San Diego	California	92102	—
Not listed	Santa Ana	California	92705	—
Not listed	Denver	Colorado	80204	—
Not listed	Cromwell	Connecticut	06416	—
Not listed	Hartford	Connecticut	06106	—
Not listed	Fort Walton Beach	Florida	32547	—
Not listed	Gainesville	Florida	32607	—
Not listed	Chicago	Illinois	60612	—
Not listed	Libertyville	Illinois	60048	—
Not listed	Boston	Massachusetts	02114	—
Not listed	Fall River	Massachusetts	02721	—
Not listed	Albuquerque	New Mexico	87109	—
Not listed	Fresh Meadows	New York	11366	—
Not listed	Staten Island	New York	10305	—
Not listed	The Bronx	New York	10467	—
Not listed	Cary	North Carolina	27518	—
Not listed	Oklahoma City	Oklahoma	73112	—
Not listed	Memphis	Tennessee	38119	—
Not listed	DeSoto	Texas	75115	—
Not listed	Richmond	Virginia	23230	—
Not listed	Brown Deer	Wisconsin	53223	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01111539, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 19, 2021 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01111539 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →